<DOC>
	<DOCNO>NCT02163993</DOCNO>
	<brief_summary>The main purpose study evaluate whether study drug know LY2951742 safe effective prevention migraine headache . The study last 28 36 week .</brief_summary>
	<brief_title>A Study LY2951742 Participants With Migraine Headache</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Participants history migraine least 1 year prior enrollment . Migraine onset prior age 50 . Current enrollment , discontinuation within last 30 day , clinical trial involve investigational drug device . Current use prior exposure CGRP antibody , antibody CGRP receptor , antibody nerve growth factor ( NGF ) . History migraine subtypes include hemiplegic migraine , ophthalmoplegic migraine , basilartype migraine . Have history presence medical illness indicate medical problem would preclude study participation . Failure respond two adequately dosed effective migraine prevention treatment . Evidence significant active psychiatric disease , opinion investigator . Women pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>